Bioavailability of different routes of drug administration
Route | Bioavailability (%) |
Intravenous | 100 |
Intramuscular | 80-100 |
Subcutaneous | 80-100 |
Oral | 5- <100 |
Rectal | 30-100 ( highly variable) |
Inhalational | 5-100 |
Sublingual | 30- <100% |
First pass metabolism is avoided in all except orally administered drugs.
It is metabolised by the enzyme cholinesterase or pseudocholinesterase in plasma to inactive forms. Inherited differences in the enzyme may slow down the breakdown of succinylcholine resulting in prolonged neuromuscular paralysis in some patients. Involved gene is located on chromosome 3 on gene E1. Most common mutation is a substitution of aspartic acid to glycine which reduces the binding of enzyme to succinylcholine. Slow and fast acetylators: Drugs like isoniazid, dapsone, hydralazine, sulfa drugs and procainamide are metabolized by acetylation reactions catalysed by enzyme acetyltransferases. Gene is NAT2. Rate of acetylation is determined by ethnicity due to polymorphisms in the enzyme. 50% of Caucasians and African Americans are slow acetylators while most Asians are fast acetylators. Slow acetylators are at risk of adverse effects while rapid acetylators are at risk of low blood levels leading to decreased response to drug therapy.
It is a common cause of liver transplantation. Large doses of acetaminophen, especially in people suffering from chronic liver disorders and in alcoholics, saturates the usual hepatic detoxification mechanisms, leading to excessive formation of a toxic metabolite called NAPQI or N-acetyl-p-benzoquinone imine. Normally, NAPQI is detoxified by glutathione. In acetaminophen overdose, glutathione stores are depleted which causes NAPQI to bind to hepatocytes causing necrosis. Chronic alcoholism induces hepatic microsomal enzymes resulting in increased formation of NAPQI. Alcohol also causes glutathione depletion. Patients may be asymptomatic up to 24 hours, presenting later on with vomiting, RUQ pain, hypotension, liver failure, renal failure, coagulopathies, metabolic acidosis and encephalopathy. Microscopically, the liver shows centrilobular necrosis. Treatment is guided by time since ingestion. Within 1 hour of ingestion, activated charcoal can be used. Blood levels of acetaminophen are measured. Definitive treatment is with N-acetyl cysteine which provides sulfhydryl groups that attach to NAPQI, hence preventing hepatic necrosis. It also reduces NAPQI to acetaminophen, acts as a precursor to glutathione, has antioxidant and anti-inflammatory properties, increases sulphate conjugation, increases local nitric oxide and oxygen delivery. Severe cases may also need hemodialysis and liver transplantation.
* Includes digoxin, ethanol, theophylline, cimetidine, gentamicin. Reduce loading dose.
** Includes diazepam, lidocaine, thiopental. Increase in half life.
Type | Description |
Primary | When chemotherapy alone can cure the cancer like in Hodgkin’s disease, Wilms tumor, small cell lung cancer, testicular cancer, Burkit’s lymphoma, large cell lymphoma, leukemias. |
Adjuvant | Administered prior to or after other methods like surgery, to increase the effectiveness of treatment, to prolong survival or decrease the risk of recurrence. |
Palliative | To minimize the discomfort caused by or slow progression of an incurable cancer |
Neoadjuvant | Given prior to surgery or radiation, to shrink the size of a tumor and make it easier to resect. |
Vinca alkaloids cause microtubule depolymerization by binding to beta tubulin resulting in apoptosis Paclitaxel binds to beta tubulin and enhances microtubule assembly, polymerization and bundling Vinca destabilizes while paclitaxel stabilizes the microtubule
Some drugs become less efficacious or lose their effects as they are continued over a period of time. It is a type of tolerance or desensitization. Mechanisms include depletion of chemicals needed for pharmacological action like neurotransmitters, changes in receptor state like phosphorylation or in receptor numbers like downregulation. Sometimes counterregulatory physiological changes may offset the action of the drug. It is seen with nitroglycerin, topical corticosteroids, local anesthetics, nicotine etc. Temporary withholding the drug or giving drug free hours can restore sensitivity.
####Metronidazole It is commonly used to treat anaerobic and protozoal infections. Metronidazole is metabolized to nitro free radicals which cause DNA damage and inhibition of protein synthesis. It is effective against E.histolytica, Trichomonas, Giardia lamblia, Bacteroides sp, Clostridium sp, Fusobacterium sp, Gardnerella vaginalis, H.pylori etc. Adverse effects include nausea, metallic taste, headache, diarrhea, pruritus, peripheral neuropathy, seizures and probable carcinogenicity. It has an antabuse like reaction if alcohol is consumed concurrently
It typically occurs 2-5 days after the initiation of warfarin therapy. It occurs due to depletion of vit K dependent anticoagulants proteins C and S. It is seen due to thrombosis in blood vessels of the skin especially in areas of fat abundance and presents with pain, purplish rash, blistering , blue toe syndrome and skin necrosis in the breast, thighs, buttocks and abdomen. Management is by stopping warfarin, vit K, heparin and protein C concentrates.
1st generation | Cefazolin, cephalexin, cefadroxil |
2nd generation | Cefaclor, cefotetan, cefoxitin, cefprozil, cefuroxime |
3rd generation | Cefdinir, ceftriaxone,cefotaxime, cefpodoxime, ceftazidime, cefixime |
4th generation | Cefepime |
5th generation | Ceftaroline |
Penicillin type | Characteristics |
Natural penicillins | Penicillin G, Penicillin V. Active against non-beta-lactamase producing Gram positive cocci like viridans streptococci, Group A streptococci, pneumococci, peptostreptococcus, Clostridia, Actinomycetes, meningococci, gonococci, Pasteurella multocida, Treponema pallidum |
Penicillinase resistant penicillins | Methicillin (not used now, causes interstitial nephritis), nafcillin, oxacillin, dicloxacillin. Active against penicillinase producing Staphylococci but no action on MRSA, MRSE and Enterococci |
Aminopenicillins | Ampicillin,amoxicillin; activity like natural penicillins plus also gram negative bacilli like H.influenzae, E.coli, Proteus, Salmonella, Shigella sp. Widespread resistance seen |
Carboxypenicillins | Carbenicillin, ticarcillin; greater Gram negative spectrum including Pseudomonas aeruginosa |
Ureidopenicillins and piperazine penicillins | Azlocillin, mezlocillin, piperacillin; coverage like carboxypenicillins plus more effective on Klebsiella, Serratia, Enterobacter, Enterococcus and P.aeruginosa; |
It binds to tubulin and blocks the assembly and polymerisation of microtubules. Colchicine also inhibits neutrophil chemotaxis and the release of a crystal-derived chemotactic factor (CCF) from neutrophil lysosomes, superoxide formation and phagocytosis.** **It is used in the treatment of acute gout, familial meditteranean fever, Behcet’s disease and inflammatory disorders. Adverse effects include diarrhea, nausea, vomiting, neutropenia, neuropathy and organ failure. Doses should be decreased in renal and/or hepatic failure. Colchicine has a narrow therapeutic index. Rhabdomyolysis can occur when given along with statins. Dose should be reduced when cyt P450 inhibitors are co-prescribed.
It is a recently FDA approved form of insulin aspart that is designed to speed up the absorption of subcutaneous insulin by adding vitamin B3 or niacin and L-arginine. It is used in type 1 and 2 DM and can be injected up to 20 minutes after starting a meal. Onset of action is within 15-20 minutes and duration of action is 7 hours.
Antidote | Uses |
Activated charcoal | Typically within 1 hour and maximum within 4 hours of oral ingestion of a toxin; can be used in carbamazepine, dapsone, theophylline, phenobarbitone, quinine etc. Do not use in alcohol, acid, alkali or metal poisoning |
Dimercaprol | Arsenic, gold, mercury and lead poisonings |
Digi-Fab (antibody to digoxin) | Digoxin toxicity |
Urinary alkalinization with sodium bicarbonate | TCA, salicylates, phenobarbital |
Naloxone | Opioids, repeat doses every 2-3 minutes, onset of action <2 minutes in intravenous dosing |
Flumazenil | Benzodiazepines |
Fomepizole | Methanol and ethylene glycol |
Pralidoxime and atropine | Organophosphorus |
N acetyl cysteine | Paracetamol |
Sodium thiosulfate | Cyanide poisoning |
Vitamin K | Warfarin |
Pyridoxine or Vit B6 | Isoniazid |
Folinic acid | Methotrexate |
Beta blockers | Theophylline |
Octreotide | Oral hypoglycemics |
Physostigmine | Anticholinergic poisoning |
Protamine sulfate | Heparin |
Glucagon, calcium, high dose insulin with glucose | Beta blockers and calcium channel blockers |
Comparison between proton pump inhibitors and H2 blockers
Treatment options for resistant bacteria
Resistance type | Treatment |
MRSA | Soft tissue infections: oral doxycycline, trimethoprim-sulfamethoxazole, clindamycin, minocycline, linezolid, tedizolid, delafloxacin, omadacycline; Complicated infections: Intravenous vancomycin, daptomycin or linezolid |
VRSA and VISA | Daptomycin, telavancin, ceftaroline, linezolid, tedizolid, oritavancin |
VRE | Ampicillin plus gentamicin/streptomycin, ceftriaxone, ampicillin-sulbactam, linezolid, daptomycin |
MDR Pseudomonas aeruginosa | Ceftazidime-avibactam, ceftolozane-tazobactam, colistin, polymyxin B, imipenem-cilastatin, relebactam |
ESBL | Carbapenems (imipenem, meropenem, ertapenem), piperacillin tazobactam, cefepime, fosfomycin (UTIs), temocillin |
Carbapenem resistant Enterobacteriaceae | Avibactam plus ceftazidime, meropenem plus vaborbactam, fosfomycin (UTIs) |